Guangzhou Lbp Medicine Science & Technology Co.Ltd(688393) in the annual report released on April 1, the company’s R & D expenses increased by 65.52% in 2021, reaching 459019 million yuan. While maintaining stable growth, increasing technology investment and innovation is very in line with the positioning direction of listed companies on the science and innovation board.
Specifically, in 2021, the company achieved a total operating revenue of 439 million yuan, a year-on-year increase of 16.93%. Excluding the impact of the share based payment fees to be accrued for the termination of equity incentive during the reporting period (excluding the impact of income tax), the net profit attributable to the shareholders of the listed company was 871311 million yuan, a year-on-year increase of 2.81%.
The R & D cost increased by 4.552 million yuan, which is worthy of attention. In terms of effectiveness, Guangzhou Lbp Medicine Science & Technology Co.Ltd(688393) independently developed detection technology platforms such as conventional pathology, liquid based cytology (LBP), immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) and PCR, covering the needs of tumor screening and diagnosis from tissue, cell to protein and molecular level. 570 registration / filing products related to pathological diagnosis have been developed, which can be used for screening and diagnosis of multiple types of tumors. It is one of the enterprises with the richest technical platforms and the largest variety of products in China’s tumor screening and diagnosis industry.
Guangzhou Lbp Medicine Science & Technology Co.Ltd(688393) chairman Cai Xiangting disclosed, “In 2022, on the basis of continuing to do a good job in the core business, the company will make efforts in three strategic new businesses, including joint construction of pathology department, pathology AI system and concomitant diagnosis. The three businesses will be based on the core technology of existing businesses and expand the Internet, AI technology and concomitant diagnosis required for accurate drug use of tumors, which is of great strategic significance to improve the company’s core competitiveness and seize the market opportunity.”
